Publications in collaboration with researchers from Hospital Clínico San Carlos de Madrid (12)

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  2. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

  3. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

2022

  1. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  2. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2019

  1. Biological and prognostic differences between symptomatic colorectal carcinomas and those detected by screening

    European Journal of Surgical Oncology, Vol. 45, Núm. 10, pp. 1876-1881

2018

  1. First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii535-viii536

  2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

  3. Outcomes of open versus laparoscopic surgery in patients with colon cancer

    European Journal of Surgical Oncology, Vol. 44, Núm. 9, pp. 1344-1353

2013

  1. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. the large experience of the spanish national tumor registry (RGETNE)

    Neuroendocrinology, Vol. 98, Núm. 2, pp. 156-168

2011

  1. Risk-adapted treatment in clinical stage I testicular seminoma: The third Spanish Germ Cell Cancer Group study

    Journal of Clinical Oncology, Vol. 29, Núm. 35, pp. 4677-4681

2010

  1. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE)

    Annals of Oncology, Vol. 21, Núm. 9, pp. 1794-1803